文献速递类风湿关节炎

严重感染后的生物制剂处方决策:英国风湿病学会生物制剂注册-类风湿关节炎研究结果

Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

研究纳入英国风湿病学会生物制剂注册-类风湿关节炎队列中在TNF抑制剂(TNFi)治疗期间发生至少一次严重感染(SI)的1583例患者,分析感染后继续、停用或换用不同作用机制生物制剂对复发性SI风险的影响。结果显示,多数患者(73%)在指数SI后60天继续使用TNFi;与停用生物制剂者相比,继续用药或换药类别者复发性SI风险显著更低(继续用药HR=0.54,95%CI:0.40,0.74;换药HR=0.29,95%CI:0.09,0.95)。

要点

  • 1583例RA患者在TNFi治疗期间发生至少一次SI,73%在指数SI后60天继续使用TNFi。
  • 复发性SI总发生率为每年25.6%(95%CI:22.5,29.2)。
  • 与停用生物制剂者相比,继续用药或换药类别者复发性SI风险显著更低。

核心结论

  • 指数SI后继续或换用TNFi的患者,复发性SI风险低于停用药物者。
  • 作者认为这可能与重新引入生物制剂后更好地控制疾病活动有关,而疾病活动是SI的驱动因素;或者也可能是将更健康的患者筛选进入重启生物制剂治疗所致。

研究设计与样本

  • 研究纳入英国风湿病学会生物制剂注册-类风湿关节炎队列中在TNFi治疗期间发生至少一次SI的患者。
  • 分析SI后的生物制剂治疗决策,采用多变量校正Cox比例风险模型识别复发性SI的预测因素及生物制剂治疗选择是否影响未来SI风险。

主要发现

  • 共1583例患者在TNFi治疗期间发生至少一次SI。
  • 多数患者(73%)在指数SI后60天记录为继续使用TNFi。
  • 复发性SI发生率为每年25.6%(95%CI:22.5,29.2)。
  • 复发性SI发生率在停用TNFi者中最高(每年42.6%,95%CI:32.5,55.7%),在换用不同类别生物制剂者中最低(每年12.1%,95%CI:3.9,37.4%)。
  • 与停用生物制剂者相比,继续用药者复发性SI风险显著更低(HR=0.54,95%CI:0.40,0.74),换药类别者亦显著更低(HR=0.29,95%CI:0.09,0.95)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To establish whether the decision to stop, continue or switch TNF inhibitor (TNFi) therapy to a biologic drug with an alternative mode of action following a serious infection (SI) impacts upon the risk of recurrent SI in patients with RA. METHODS: Patients recruited to the British Society for Rheumatology Biologics Register-RA with at least one episode of SI while on TNFi were included. The biologic treatment decision following SI was considered. A multivariable adjusted Cox proportional hazards model was used to identify predictors of recurrent SI and whether biologic treatment choices influenced future SI risk. RESULTS: In total, 1583 patients suffered at least one SI while on TNFi. Most patients (73%) were recorded as continuing TNFi 60 days after an index SI. The rate of recurrent SI was 25.6% per annum (95% CI: 22.5, 29.2%). The rate of recurrent SI was highest in patients who stopped their TNFi (42.6% per annum, 95% CI: 32.5, 55.7%) and lowest in those who switched biologic drug class (12.1% per annum, 95% CI: 3.9, 37.4%). Compared with patients stopping biologic therapy, patients who continued or switched drug class had significantly lower risk of recurrent SI (drug continuation hazard ratio = 0.54, 95% CI: 0.40, 0.74; drug switch hazard ratio = 0.29, 95% CI: 0.09, 0.95). CONCLUSIONS: Patients who continued or switched their TNFi post-index SI had a lower risk of recurrent SI infection compared with those who stopped the drug. This may be explained by better control of disease activity with reintroduction of biologic therapy, a driving factor for SI or alternatively channelling fitter patients to restart biologic therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Subesinghe S, Rutherford AI, Byng-Maddick R, et al. Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford). 2018. PMID: 29986108. doi:10.1093/rheumatology/key198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。